# Cellply: Research, Bologna, Italy

> Cellply: Cellply is a DeepTech biotechnology company based in Bologna, Italy, founded in 2013 by Massimo Bocchi and Roberto Guerrieri. Based in Bologna, Italy.

Source: https://millionrounds.com/startup/cellply (Millionrounds; every figure on the page links to its filing or article)

Italy · [Research startup](https://millionrounds.com/companies)

# Cellply

Cellply is a DeepTech biotechnology company based in Bologna, Italy, founded in 2013 by Massimo Bocchi and Roberto Guerrieri.

Email

Funding reported Last round: Undisclosed round

Research Bologna, Italy

Follow Cellply and see its new rounds in your feed. [Start following](https://millionrounds.com/login?join=1&why=follow&next=%2Fstartup%2Fcellply)

Company summary

- **Founded:** 2013 13 years old
- **Team:** 28 11 to 50 people
- **Funding reported:** 11.7M as listed, currency not stated
- **Last round:** Undisclosed round Sept 2023

How sure we are

- ✓ **Listed** We know it exists and what it does
- 2 **Funding reported** A company dataset reports a raise
- 3 **Observed** A filing or a dated announcement confirms a round

No round for Cellply has been confirmed by a filing or an announcement yet, so nothing here counts toward an investor's record. [How we decide](https://millionrounds.com/methodology)

## About Cellply

Cellply is a DeepTech biotechnology company based in Bologna, Italy, founded in 2013 by Massimo Bocchi and Roberto Guerrieri.

The company focuses on developing advanced analytical tools that characterize the functionality of single immune and tumor cells at a single-cell resolution. Cellply aims to enhance the development of immunotherapies and cell-based therapies by unraveling the complexities of the immune system. The company's flagship product, VivaCyte®, is a fully automated analytical platform that integrates microfluidics, AI-based image analysis, and robotics. This platform supports the development, manufacturing, and quality control of next-generation cell therapies. Cellply also offers services in single-cell potency characterization, in-vitro functional assays, immune cell function profiling, and predictive diagnostics, catering primarily to biopharmaceutical companies, research institutes, and clinicians. With significant funding secured for expansion, Cellply is recognized as an innovative startup in the life sciences sector.

## What company datasets say Cellply raised

Funding, as reported

Reported in all **11.7M** in the source's currency

Rounds **6**

Last round **Undisclosed round**

Last round size **7.9M**

Last round date **Sept 2023**

Investors listed **10**

## Founders and team

From Cellply's own website: 1 founder, 11 on the team.

**Massimo Bocchi** Co-Founder and Chief Operating Officer

- **Alex Jones** Chief Executive Officer
- **Alessia Zanelli** President
- **Andrea Faenza** Chief Technology Officer
- **Priyanka Dutta Passecker** Chief Business Officer
- **Laura Rocchi** Head of Biology
- **Antonella Beltrame** Board Member
- **Carmelo Catalano** Board Member
- **Marco Fadda** Business Development Manager EMEA/APAC
- **Miro Venturi** Board Member
- **Paola Poggi** Operations & PMO Manager
- **Teresa De Nadai** Board Member

## On 2 portfolio pages

Investors who name them

- [B-Engine](https://millionrounds.com/fund/b-engine)
- [CMMVentures](https://millionrounds.com/fund/cmmventures)

Each firm lists Cellply on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.

## The company, in detail

What they build

Known for

cell characterization platform health care singlecell biotechnology research cell therapy single-cell sample throughput cell function analysis single-cell analysis hospital & health care automated analysis medical cell therapy discovery tools health biotechnology potency cell therapy development

Built with from their website

Google Maps Google Tag Manager WordPress.org Atlassian Viewport Meta Visual Composer Next.js Google Maps (Non Paid Users) Hubspot Vimeo

+8 more

GoDaddy Domains webpack Wordpress Microsoft Exchange Online Priority Hints React CAPTCHA Workable

- **Sector:** Research
- **Industry code:** NAICS 541714, 334516, SIC 3824, 8731, 3826
- **Region:** Emilia-Romagna
- **Revenue:** 7.5M a year, as listed
- **Full record:** [Every detail in the company directory](https://millionrounds.com/directory/cellply)

## Research in Italy

Startups like it

- [**Genespire** Milan · founded 2020](https://millionrounds.com/startup/genespire)
- [**Aptadir Therapeutics** Milano](https://millionrounds.com/startup/aptadir-therapeutics)
- [**Resalis Therapeutics** Turin · founded 2021](https://millionrounds.com/startup/resalis-therapeutics)
- [**Sibylla Biotech** Bresso · founded 2017](https://millionrounds.com/startup/sibylla-biotech)
- [**Algorithmiq** Milano · founded 2020](https://millionrounds.com/startup/algorithmiq)
- [**Phononic Vibes** Milan · founded 2018](https://millionrounds.com/startup/phononic-vibes-2)
- [**Contraria Biotech** Siena · founded 2017](https://millionrounds.com/startup/contraria-biotech)
- [**Altheia Science** Milan · founded 2017](https://millionrounds.com/startup/altheia-science)

## Is this your company?

Add your raise, your deck and your story, and put Cellply in front of investors. Or tell us what we have wrong.

[List your startup](https://millionrounds.com/list-your-startup)[Send a correction](https://millionrounds.com/corrections)